Keros Therapeutics (KROS) grants director stock options and RSU awards

Rhea-AI Filing Summary

Keros Therapeutics director Charles W. Newton received new equity awards. He was granted stock options covering 14,788 shares of Common Stock at an exercise price of $11.35 per share, expiring on March 8, 2036, and 13,215 restricted stock units.

The RSUs vest over three years in twelve equal quarterly installments starting on May 15, 2026, while the options vest over three years in equal quarterly installments starting on June 9, 2026, in each case subject to his continuous service. Following these awards, he directly holds 14,788 options and 13,215 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Newton Charles W.

(Last) (First) (Middle)

C/O KEROS THERAPEUTICS, INC.

1050 WALTHAM STREET, SUITE 302

(Street)

LEXINGTON MA 02421

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Keros Therapeutics, Inc. [ KROS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/09/2026		A		13,215(1)	A	$0	13,215	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$11.35	03/09/2026		A		14,788		(2)	03/08/2036	Common Stock	14,788	$0	14,788	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award. The RSUs shall vest over a three-year period in twelve equal quarterly installments with the first such vesting to occur on May 15, 2026, subject to the Reporting Person's continuous service through each such vesting date.

2. The shares subject to the option shall vest over a three-year period in equal quarterly installments with the first such vesting to occur on June 9, 2026, subject to the Reporting Person's continuous service through each such vesting date.

	/s/ Esther Cho, Attorney-in-Fact	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Keros Therapeutics (KROS) report for Charles W. Newton?

Keros Therapeutics reported that director Charles W. Newton received two equity awards: stock options for 14,788 shares of Common Stock at an exercise price of $11.35, and 13,215 restricted stock units, all recorded as direct ownership grants on March 9, 2026.

How do Charles W. Newton’s new RSUs at Keros Therapeutics (KROS) vest?

The 13,215 restricted stock units granted to Charles W. Newton vest over a three-year period in twelve equal quarterly installments. The first vesting date is May 15, 2026, and each installment requires his continuous service through the applicable vesting date.

What are the terms of Charles W. Newton’s new stock options in Keros Therapeutics (KROS)?

Newton’s stock options cover 14,788 shares of Common Stock with an exercise price of $11.35 per share and an expiration date of March 8, 2036. They vest in equal quarterly installments over three years, beginning on June 9, 2026, subject to continued service.

What is Charles W. Newton’s direct equity position in Keros Therapeutics (KROS) after these awards?

After these awards, Charles W. Newton directly holds 13,215 shares of Common Stock and stock options for 14,788 underlying shares. These positions reflect the totals following the grants reported in the Form 4 filed for March 9, 2026.

Are Charles W. Newton’s Keros Therapeutics (KROS) awards open-market purchases or compensation grants?

The transactions are coded as “A”, described as grant, award, or other acquisition, indicating they are equity awards rather than open-market purchases. Both the RSUs and stock options were awarded at a transaction price of $0.00 per share to the reporting person.